Literature DB >> 15557156

Tolerance induction by veto CTLs in the TCR transgenic 2C mouse model. I. Relative reactivity of different veto cells.

Shlomit Reich-Zeliger1, Esther Bachar-Lustig, Judith Gan, Yair Reisner.   

Abstract

Several bone marrow cells and lymphocyte subpopulations, known as veto cells, were shown to induce transplantation tolerance across major histocompatibility Ags. Due to the low frequency of the effector T cells against which the veto cells inhibitory activity is aimed, the fate of the effector cells was traditionally followed indirectly by functional limiting dilution assays, which are cumbersome and depend on numerous parameters. In the present study the fate of the effector T cells was monitored directly by FACS, using TCR transgenic mouse CD8(+) T cells in which the transgene is directed against H-2(d) (the 2C model). This assay is validated by demonstrating the potency, selectivity, radiation sensitivity, and contact dependency of anti-third-party CTLs previously demonstrated by the limiting dilution assay. In contrast to veto CTLs, nonactivated CD8(+) T cells lack veto activity. Comparison by FACS in the 2C model revealed a hierarchy of veto cells, in the order of veto CTLs activated NK cells, activated CD4(+) T cells, and activated B cells. The latter cells as well as nonactivated CD4(+) or NK cells were shown to be completely devoid of veto activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557156     DOI: 10.4049/jimmunol.173.11.6654

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  CTLs respond with activation and granule secretion when serving as targets for T-cell recognition.

Authors:  Oren Milstein; David Hagin; Assaf Lask; Shlomit Reich-Zeliger; Elias Shezen; Eran Ophir; Yaki Eidelstein; Ran Afik; Yaron E Antebi; Michael L Dustin; Yair Reisner
Journal:  Blood       Date:  2010-11-02       Impact factor: 22.113

2.  Induction of tolerance to bone marrow allografts by donor-derived host nonreactive ex vivo-induced central memory CD8 T cells.

Authors:  Eran Ophir; Yaki Eidelstein; Ran Afik; Esther Bachar-Lustig; Yair Reisner
Journal:  Blood       Date:  2009-12-30       Impact factor: 22.113

3.  Gammadelta T cells do not require fully functional cytotoxic pathways or the ability to recognize recipient alloantigens to prevent graft rejection.

Authors:  Sanja Vodanovic-Jankovic; William R Drobyski
Journal:  Biol Blood Marrow Transplant       Date:  2006-11       Impact factor: 5.742

4.  Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells.

Authors:  Eran Ophir; Noga Or-Geva; Irina Gurevich; Orna Tal; Yaki Eidelstein; Elias Shezen; Raanan Margalit; Assaf Lask; Guy Shakhar; David Hagin; Esther Bachar-Lustig; Shlomit Reich-Zeliger; Andreas Beilhack; Robert Negrin; Yair Reisner
Journal:  Blood       Date:  2012-12-05       Impact factor: 22.113

5.  Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway.

Authors:  Jacopo Mariotti; Jason Foley; Kaitlyn Ryan; Nicole Buxhoeveden; Veena Kapoor; Shoba Amarnath; Daniel H Fowler
Journal:  Blood       Date:  2008-07-14       Impact factor: 22.113

6.  Induction of B-cell immune tolerance by antigen-modified cytotoxic T lymphocytes.

Authors:  Phuong Nguyen; Terrence L Geiger
Journal:  Transplantation       Date:  2010-03-27       Impact factor: 4.939

7.  A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells.

Authors:  David H Quach; Luis Becerra-Dominguez; Rayne H Rouce; Cliona M Rooney
Journal:  J Transl Med       Date:  2019-07-24       Impact factor: 5.531

8.  The use of donor-derived veto cells in hematopoietic stem cell transplantation.

Authors:  Eran Ophir; Yair Reisner
Journal:  Front Immunol       Date:  2012-05-02       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.